NICM
INO icon

Neo Ivy Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Neo Ivy Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-45
Closed -$15K – 521
2021
Q3 		$15K Buy
+45
New +$4.52K 0.02% 402
2020
Q4 		– Sell
-140
Closed -$19K – 490
2020
Q3 		$19K Buy
140
+95
+211% +$19.8K 0.02% 418
2020
Q2 		$15K Buy
+45
New +$7.23K 0.02% 402

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Neo Ivy Capital Management's INO Position: Q4 2021 in Review

Neo Ivy Capital Management sold out of Inovio Pharmaceuticals (INO) in Q4 2021, closing a stake of 45 shares — an estimated $15K sold.

Neo Ivy Capital Management first reported a position in INO in Q2 2020 and held it in 3 quarters. The position peaked at $19K in Q3 2020. 208 funds tracked by Wall St. Rank hold INO as of Q4 2021.

  • Neo Ivy Capital Management reported no remaining Inovio Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Neo Ivy Capital Management sold 45 Inovio Pharmaceuticals shares in Q4 2021, an estimated $15K.
  • Neo Ivy Capital Management first reported a position in Inovio Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • Neo Ivy Capital Management's Inovio Pharmaceuticals position peaked at $19K in Q3 2020.
  • 208 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2021.

Based on Neo Ivy Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.